Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK interaction of clesacostat and ervogastat in healthy adults
NCT03534648Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of clesacostat and ervogastat in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to End of Dosing Interval at Day 14 and Maximum observed concentration at Day 14. Started Apr 2018; status: completed.
02
Drugs
clesacostatervogastat
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03534648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03534648.